Safety and Pharmacokinetics of the Oral TYK2 Inhibitor PF‐06826647: A Phase I, Randomized, Double‐Blind, Placebo‐Controlled, Dose‐Escalation Study

• Autores principales: Ravi Shankar P. Singh (Autor), Vivek Pradhan (Autor), Erika S. Roberts (Autor), Matthew Scaramozza (Autor), Elizabeth Kieras (Autor), Jeremy D. Gale (Autor), Elena Peeva (Autor), Michael S. Vincent (Autor), Anindita Banerjee (Autor), Andrew Fensome (Autor), Martin E. Dowty (Autor), Peter Winkle (Autor), Christopher Tehlirian (Autor)
• Formato: Libro
• Publicado: Wiley, 2021-03-01T00:00:00Z.
• Materias: article
• Acceso en línea: Connect to this object online.

Selective inhibition of tyrosine kinase 2 (TYK2) may offer therapeutic promise in inflammatory conditions, with its role in downstream pro‐inflammatory cytokine signaling. In this first‐in‐human study, we evaluated the safety, tolerability, and pharmacokinetics (PK) of a novel TYK2 inhibitor, PF‐068...